LT2020521A - Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui - Google Patents

Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui

Info

Publication number
LT2020521A
LT2020521A LT2020521A LT2020521A LT2020521A LT 2020521 A LT2020521 A LT 2020521A LT 2020521 A LT2020521 A LT 2020521A LT 2020521 A LT2020521 A LT 2020521A LT 2020521 A LT2020521 A LT 2020521A
Authority
LT
Lithuania
Prior art keywords
vpa
dca
combination
inhibition
tumor
Prior art date
Application number
LT2020521A
Other languages
English (en)
Other versions
LT6874B (lt
Inventor
Donatas STAKIŠAITIS
Angelija VALANČIŪTĖ
Ingrida BALNYTĖ
Vaiva LESAUSKAITĖ
Milda JUKNEVIČIENĖ
Jūratė STANEVIČIŪTĖ
Darius Juozas Jasaitis
Original Assignee
Lietuvos Sveikatos Mokslu Universitetas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lietuvos Sveikatos Mokslu Universitetas filed Critical Lietuvos Sveikatos Mokslu Universitetas
Priority to LT2020521A priority Critical patent/LT6874B/lt
Priority to EP21168796.7A priority patent/EP3895702A1/en
Publication of LT2020521A publication Critical patent/LT2020521A/lt
Publication of LT6874B publication Critical patent/LT6874B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Išradimas susijęs su valpro rūgšties (VPA) ir dichloroacetato (DCA) druskų derinio (VPA–DCA) taikymu terapijai gydant vėžį. Pagrindinis DCA priešvėžinio veikimo mechanizmas yra piruvato dehidrogenazės kinazių inhibicija, slopinama pieno rūgšties produkcija ląstelėje ir kraujyje, o VPA – histono deacetilazių inhibicija, epigenetinis poveikis DNR acetilinimui ir metilinimui. Abu tiriamieji vaistiniai preparatai slopina oksidacinę glikolizę, Na-K-2Cl nešiklio RNR raišką ląstelėje, didina oksidacinį stresą navikinėse ląstelėse, indukuoja jų apoptozę, slopina ląstelių proliferaciją. VPA–DCA derinys mažina gliukozės koncentraciją kraujo serume, natrio ir chlorido jonų kiekį ląstelėje ir ekstraląsteliniame tarpe. Šio derinio sudedamųjų dalių farmakologinis sinergizmas slopina naviko ląstelių proliferaciją, neoangiogenezę, naviko augimą, jo invaziją. VPA–DCA, kaip papildomas vaistinis preparatas, gali būti taikomas chemoterapijos ir spindulinio gydymo veiksmingumui pagerinti ir naviko rezistentiškumą gydymui atitolinti.
LT2020521A 2020-04-17 2020-04-17 Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui LT6874B (lt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LT2020521A LT6874B (lt) 2020-04-17 2020-04-17 Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui
EP21168796.7A EP3895702A1 (en) 2020-04-17 2021-04-16 Derivative of valproic acid and dichloroacetate used for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2020521A LT6874B (lt) 2020-04-17 2020-04-17 Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui

Publications (2)

Publication Number Publication Date
LT2020521A true LT2020521A (lt) 2021-10-25
LT6874B LT6874B (lt) 2021-12-10

Family

ID=76374857

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2020521A LT6874B (lt) 2020-04-17 2020-04-17 Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui

Country Status (2)

Country Link
EP (1) EP3895702A1 (lt)
LT (1) LT6874B (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311548A1 (en) * 2022-07-29 2024-01-31 B & A Therapeutics Combination of a nkcc1 protein inhibitor and a microtubule inhibitor for use in the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077353A1 (en) 2004-01-16 2005-08-25 The Governors Of The University Of Alberta Dichloroacetate in combination with an inotrope for cardioprotection
US20090252790A1 (en) 2006-05-13 2009-10-08 Novo Nordisk A/S Tablet formulation
CN101516347A (zh) 2006-09-29 2009-08-26 诺沃-诺迪斯克有限公司 包含二甲双胍和瑞格列奈的药物制剂
US8607724B2 (en) 2011-06-07 2013-12-17 Gyro-Gale Corporation Rudder assembly with a deflectable trailing tab
US9556113B2 (en) 2014-04-29 2017-01-31 The South Dakota Board Of Regents Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment

Also Published As

Publication number Publication date
EP3895702A1 (en) 2021-10-20
LT6874B (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
Su et al. Anticancer activity of sulforaphane: the epigenetic mechanisms and the Nrf2 signaling pathway
Cheishvili et al. DNA demethylation and invasive cancer: implications for therapeutics
Wen et al. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target
Weng et al. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia
Yungang et al. miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC)
Tuli et al. Molecular mechanisms behind ROS regulation in cancer: A balancing act between augmented tumorigenesis and cell apoptosis
Garcia et al. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
K Li et al. DNA methylation as a target of epigenetic therapeutics in cancer
Fernandez et al. De novo DNA methyltransferases: oncogenes, tumor suppressors, or both?
Vigetti et al. Hyaluronan synthases posttranslational regulation in cancer
Zhong et al. Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma
Taghizadeh-Hesary et al. Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity
Zhang et al. The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers
LT2020521A (lt) Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui
Hou et al. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility
Sood et al. Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines
Li et al. DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation
Yang et al. Iodine‑125 irradiation inhibits invasion of gastric cancer cells by reactivating microRNA‑181c expression
Liu et al. 5-Aza-2′'-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced RASSF1A gene
Qureshi et al. Role of DNA Methyltransferases (DNMTs) in metastasis
Yadav et al. Interplay between DNA methyltransferase 1 and microRNAs during tumorigenesis
Price et al. UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology
Yang et al. Epigenetic targets of polyphenols in cancer
Ling et al. HDAC-an important target for improving tumor radiotherapy resistance
Krawczyk et al. 5-Azacytidine for the treatment of myelodysplastic syndromes

Legal Events

Date Code Title Description
BB1A Patent application published

Effective date: 20211025

FG9A Patent granted

Effective date: 20211210